Main contents starts here
Annual Reports
2011 Annual Report
[Message and Interview] Yasuchika Hasegawa, President & CEO
“The 2011-2013 Mid-Range Plan”
Innovation
Shigenori Ohkawa, Ph.D., Chief Scientific Officer /
“The Shonan Research Center”
Culture
[Interview] Toyoji Yoshida, Chief Administration Officer
Growth
[Interview] Frank Morich, M.D., Ph.D., International Operations (Americas/Europe)
Corporate Activities and Achievements in Fiscal 2010
Contribution to Society through Pharmaceutical Business
[Interview] Haruhiko Hirate, International Operations (Asia)
Relationship with Our Stakeholders
Management Organization
Financial Section
2011 CSR Data Book
Culture
[Interview] Toyoji Yoshida, Chief Administration Officer
Organizational Governance
Human Rights
Labor Practices
The Environment
Fair Operating Practices
Consumer Issues
Community Involvement and Development
2010 Annual Report
Feature:Transformation into a New Takeda
Corporate Activities and Achievements in Fiscal 2009
Contribution to Society through Pharmaceutical Business
Relationship with Our Stakeholders
Management Organization
Financial Section
2010 CSR Data Book
Relationship with Society
Relationship with Environment
Relationship with Business Partners
Relationship with Employees
2009 Annual Report
Feature: Launching Takeda as a World-Class Pharmaceutical Company
Corporate Activities and Performance in Fiscal 2008
Contribution to Society through Pharmaceutical Business
Relationship with Our Stakeholders
Management Organization
Financial Section
2009 CSR Data Book
Relationship with Society
Relationship with Environment
Relationship with Suppliers
Relationship with Employees
2008 Annual Report
Corporate Activities and Performance in Fiscal 2007
Contribution to Society through Pharmaceutical Business
Relationship with Our Stakeholders
Financial Section
2007 Annual Report
Corporate Activities and Performance of Fiscal 2006
Contribution to Society through Pharmaceutical Business
Relationship with Our Stakeholders
Financial Section
2006 Annual Report
Corporate Activities and Performance of Fiscal 2005
Contribution to Society through Pharmaceutical Business
Relationship with Our Stakeholders
Financial Section
Skip side navigation
Stock
02/03 15:00 (TSE 1st)
Value
3,320 JPY
Net change
-15 JPY
JIJI PRESS,LTD
